



# Impact of COSD on Cancer Registration

NCIN Sarcoma Workshop  
18 January 2013

Dr Gill Lawrence, Director  
West Midlands Cancer Intelligence Unit

Tel: 0121 415 8129

e-mail: [gill.lawrence@wmciu.nhs.uk](mailto:gill.lawrence@wmciu.nhs.uk)

# The UK's National Cancer Registration System



- 8 'regional' English cancer registers + Wales, Scotland, N Ireland [& Eire]

record all malignant (invasive and *in situ*) and some benign cancers in their residents

- Core data  
Surveys

BUT

this is all changing in 2013

- approximately 150,000 new cases each year

- WMCIU holds the second largest regional register and fifth largest European register

- In 2013 the regional cancer registries are moving to a single cancer registration database for England

ENCORE

- From 1 January 2013 there will be a new cancer registration dataset

COSD

# Data sources - patient-level data

## National Feeds



Radiotherapy Data (RTDS)

Cancer Waiting Times

Chemotherapy Dataset (SACT)

ONS - Cancer and non-cancer deaths

Cancer screening programmes - Bowel, Cervix and Breast

National PET-CT imaging

National cancer audits - Lung, Head and Neck, Upper GI and Colorectal

Hospital Episode Statistics (HES)

## Local Feeds



Data from MDT software systems

Pathology full-text reports

Local imaging systems

Patient Administration Systems

Local clinical data systems

## National Pilots

Recurrent/Metastatic Breast Pilot


CRUK Stratified Medicine



Encore



# COSD – Mandatory from 1 January 2013



# What's different about the COSD?



- **Complete patient pathway**
  - Referral details for all cases
  - All treatments
  - Includes palliative and supportive care
- **Additional core data items including**
  - Involvement of Clinical Nurse Specialist
  - Duration of symptoms
    - ❖ Mandatory for Children, Teenagers, Young Adults (CTYA), Optional for others
    - ❖ Year/Month/Day as appropriate or available
- **All registerable conditions including**
  - In situ bladder, in situ melanoma, benign brain tumours
- **Includes recurrences**
  - Breast cancers to start with
- **Site specific data**
  - Key site specific clinical items – patient management
  - Site specific stage
  - Stage components of RCPATH datasets



# COSD Dataset

Data Item Name	Suggested System/Source
Primary Diagnosis (ICD)	MDT
Multidisciplinary Team Discussion Date (Cancer)	
Cancer Care Plan Intent	
Performance Status (Adult)	
TNM Stage Grouping (Final Pre Treatment)	
Site Code (Of Imaging)	Radiology
Procedure Date (Cancer Imaging)	
Imaging Code (Nicip)	
Cancer Imaging Modality	
Imaging Anatomical Site	PAS
Consultant Code	
Care Professional Main Specialty Code	
Procedure Date	Pathology
Primary Procedure (Opcs)	
Procedure (Opcs)	
Investigation Result Date	
Service Report Identifier	National Feeds – datasets and other sources e.g. CWT, RTDS, SACT, (ONS)
Service Report Status	
Care Professional Code (Pathology Test Requested By)	
Organisation Site Code (Pathology Test Requested By)	
Cancer Treatment Event Type	
Treatment Start Date (Cancer)	
Cancer Treatment Modality	
Organisation Site Code (Provider Treatment Start Date (Cancer)	



**MDT**



**Radiology**



**PAS**



**Pathology**



**National Feeds – datasets and other sources e.g. CWT, RTDS, SACT, (ONS)**

# How will data reach the registries?



- Multiple Trust systems (MDT, PAS, Path, RIS)
  - ❖ Separate files for MDT, PAS, Path, RIS
  - ❖ Compiled by registries into a full patient record
- Method of transmission
  - ❖ Agreed with registries –
    - Data Transfer Agreements
  - ❖ Secure transmission - nhs.net
  - ❖ Aim towards XML
  - ❖ Path data extracted from path reports by registries
- Minimising duplication of data flows

# Sarcoma specific data items



Sarcoma Specific Data Items		
Data item No.	Data Item Section	Data Item Name
SA11000	SARCOMA - DIAGNOSIS	<b>SARCOMA TUMOUR SITE (BONE)</b>
SA11010	SARCOMA - DIAGNOSIS	<b>SARCOMA TUMOUR SUBSITE (BONE)</b>
SA11080	SARCOMA - DIAGNOSIS	<b>SARCOMA TUMOUR SITE (SOFT TISSUE)</b>
SA11090	SARCOMA - DIAGNOSIS	<b>SARCOMA TUMOUR SUBSITE (SOFT TISSUE)</b>
SA11025	SARCOMA - DIAGNOSIS	<b>MULTIFOCAL OR SYNCHRONOUS TUMOUR INDICATOR</b>
SA11200	SARCOMA - PATHOLOGY	<b>INVESTIGATION RESULT DATE</b>
SA11210	SARCOMA - PATHOLOGY	<b>SERVICE REPORT IDENTIFIER</b>
SA11120	SARCOMA - PATHOLOGY	<b>HISTOPATHOLOGICAL TUMOUR GRADE</b>
SA11170	SARCOMA - PATHOLOGY	<b>GENETIC CONFIRMATION INDICATOR</b>
SA11130	SARCOMA - PATHOLOGY - BONE	<b>EXTENT OF LOCAL SPREAD (BONE)</b>
SA11140	SARCOMA - PATHOLOGY - BONE	<b>TUMOUR NECROSIS</b>
SA11160	SARCOMA - PATHOLOGY - BONE	<b>TISSUE TYPE AT NEAREST MARGIN</b>
SA11100	SARCOMA - PATHOLOGY - SOFT TISSUE	<b>TUMOUR DEPTH</b>

Children Teenagers Young Adults Specific Data Items		
Data item No.	Data Item Section	Data Item Name
CT6470	OSTEOSARCOMA and EWINGS	<b>SARCOMA TUMOUR SITE (BONE)</b>
CT6440	OSTEOSARCOMA and EWINGS	<b>SARCOMA TUMOUR SUBSITE (BONE)</b>
CT6380	RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	<b>SARCOMA TUMOUR SITE (SOFT TISSUE OTHER THAN RHABDOMYOSARCOMA)</b>
CT6390	RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	<b>SARCOMA TUMOUR SUBSITE (SOFT TISSUE OTHER THAN RHABDOMYOSARCOMA)</b>
CT6350	RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	<b>IRS POST SURGICAL GROUP</b>
CT6360	RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	<b>CYTOGENETICS FOR ALVEOLAR RHABDOMYOSARCOMA</b>
CT6370	RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	<b>RHABDOMYOSARCOMA SITE PROGNOSIS CODE</b>
CT6400	OSTEOSARCOMA	<b>PRIMARY TUMOUR SIZE (Radiological)</b>
CT6410	OSTEOSARCOMA	<b>EXTENT OF NECROSIS AFTER CHEMOTHERAPY</b>
CT6420	OSTEOSARCOMA	<b>SARCOMA SURGICAL MARGIN ADEQUACY</b>
CT6450	EWINGS	<b>TUMOUR VOLUME AT DIAGNOSIS</b>
CT6460	EWINGS	<b>CYTOGENETICS FOR EWINGS SARCOMA</b>






# Why is COSD important? – Bone cancer data completeness 2007-2009




% Complete		Registry							
		ECRIC	NWCIS	NYCRIS	OCIU	SWCIS	Thames	Trent	WMCUI
Patient details	Sex	100%	100%	100%	100%	100%	100%	100%	100%
	Age at diagnosis	100%	97%	100%	100%	100%	100%	100%	100%
	NHS number	98%	100%	100%	100%	100%	98%	99%	99%
	Ethnicity	54%	95%	62%	85%	91%	86%	91%	93%
Tumour details	Morphology	94%	70%	99%	82%	86%	94%	94%	99%
	Morphology coding system (ICDM 3)	61%	45%	69%	0%	0%	0%	0%	100%
	Laterality	89%	79%	99%	80%	88%	95%	93%	100%
	Detailed Site Code	92%	73%	97%	87%	93%	84%	89%	97%
Diagnosis information	Basis of diagnosis	90%	78%	95%	82%	86%	91%	87%	97%
	Cases registered from more than a death certificate	100%	99%	100%	100%	100%	99%	97%	100%
	Diagnosis dates	95%	96%	100%	100%	100%	98%	100%	97%
Treatment data	Surgery	44%	44%	74%	62%	54%	75%	47%	65%
	Radiotherapy	12%	20%	20%	19%	10%	12%	5%	10%
	Chemotherapy	34%	29%	38%	16%	38%	29%	37%	38%
	Neo-adjuvant therapy	0%	0%	0%	0%	0%	0%	0%	23%
Death data	Cause of death	100%	99%	100%	100%	100%	99%	96%	99%
	Place of death	100%	98%	98%	46%	44%	65%	98%	92%
Staging data	Tumour size	20%	0%	0%	0%	7%	11%	0%	47%
	T component	1%	0%	0%	0%	1%	1%	0%	1%
	Nodes examined	1%	0%	1%	0%	3%	1%	0%	3%
	Nodes positive	1%	3%	4%	0%	1%	0%	0%	3%
	N component	1%	0%	0%	0%	1%	0%	0%	1%
	Metastases ("Yes" or "No")	0%	0%	12%	1%	7%	68%	0%	10%
	M component	0%	0%	0%	1%	7%	0%	0%	0%
	Grade	34%	20%	22%	26%	32%	5%	0%	63%
TNM stage	1%	0%	1%	1%	7%	0%	0%	2%	


# Bone cancer – data completeness




**Figure 4.2.3 Morphology completeness by cancer registry**




**Figure 4.6.1 Tumour size completeness by cancer registry**



**Figure 4.6.8 Grade completeness by cancer registry**



**Figure 4.6.9 TNM value completeness by cancer registry**



# Why is COSD important? – Soft tissue sarcoma data completeness 2007-2009



		% Complete								
		Data item	ECRIC	NWCIS	NYCRIS	OCIU	SWCIS	Thames	Trent	WMCIU
Patient details	Sex		100%	100%	100%	100%	100%	100%	100%	100%
	Date of Birth		100%	96%	100%	100%	100%	100%	100%	100%
	NHS number		100%	99.6%	99.9%	99.8%	99.9%	98.2%	99.9%	99.8%
	Ethnicity		54%	86%	63%	83%	88%	82%	86%	89%
Tumour details	Morphology coding system (ICDM 3)		52%	35%	71%	0%	0%	0%	0%	100%
	Laterality		93%	83%	96%	91%	91%	94%	96%	99%
	Detailed Site Code		86%	80%	85%	79%	84%	71%	88%	85%
Diagnosis Information	Basis of diagnosis (histology)		95%	90%	97%	96%	96%	94%	95%	97%
	Cases registered from more than a death certificate		100%	98.5%	99.8%	99.7%	99.9%	99.2%	98.7%	100%
	Diagnosis dates		99%	97%	100%	100%	100%	98%	100%	96%
Treatment data	Surgery		67%	60%	75%	73%	73%	78%	47%	70%
	Radiotherapy		20%	15%	28%	14%	16%	15%	7%	26%
	Chemotherapy		20%	14%	20%	16%	16%	14%	17%	12%
	Neo-adjuvant therapy		0%	0%	0%	0%	0%	0%	0%	2%
Death data	Cause of death		100%	99%	100%	100%	99%	99%	95%	100%
	Place of death		100%	98%	97%	47%	47%	73%	100%	96%
Staging data	Tumour size		34%	1%	1%	2%	29%	12%	0%	47%
	T component		3%	0%	0%	1%	5%	3%	0%	12%
	Nodes examined		5%	0%	1%	1%	5%	5%	0%	6%
	Nodes positive		1%	1%	0%	0%	1%	1%	0%	2%
	N component		1%	0%	0%	6%	15%	2%	0%	7%
	Metastases ("Yes" or "No")		0%	0%	18%	3%	9%	61%	0%	16%
	M component		2%	1%	0%	4%	10%	1%	0%	8%
	Grade		44%	33%	34%	31%	51%	10%	2%	45%
TNM stage		1%	1%	3%	3%	9%	0%	0%	8%	

# Most common soft tissue sarcoma variants



Morphology	88903	88003	91403	88503	88323	89303	88013	88113	91203	89903	88513	88303	89363	
Description	Leiomyosarcoma, NOS	Sarcoma, NOS	Kaposi's sarcoma	Liposarcoma, NOS	Dermatofibrosarcoma	Endometrial stromal sarcoma	Spindle cell sarcoma	Fibromyxosarcoma	Haemangiosarcoma	Mesenchymoma, malignant	Liposarcoma, well differentiated	Fibrous histiocytoma, malignant	Gastrointestinal stromal sarcoma	5 Most common types
ECRIC	21%	12%	3%	5%	5%	3%	5%	4%	2%	7%	2%	2%	0%	50%
NWCIS	18%	13%	5%	5%	6%	1%	4%	4%	5%	4%	4%	2%	1%	52%
NYCRIS	17%	14%	2%	5%	6%	2%	4%	3%	3%	2%	7%	1%	5%	49%
OCIU	17%	12%	2%	12%	3%	3%	4%	3%	2%	7%	4%	3%	0%	53%
SWCIS	17%	12%	3%	7%	4%	3%	4%	5%	4%	5%	2%	3%	0%	47%
Thames	14%	10%	12%	5%	6%	12%	4%	3%	3%	0%	1%	3%	0%	53%
Trent	19%	11%	4%	2%	6%	3%	2%	5%	4%	6%	3%	2%	0%	48%
WMCIU	17%	6%	3%	3%	4%	1%	8%	2%	6%	0%	5%	8%	8%	46%
<b>Grand Total</b>	<b>17%</b>	<b>11%</b>	<b>5%</b>	<b>5%</b>	<b>5%</b>	<b>5%</b>	<b>4%</b>	<b>4%</b>	<b>4%</b>	<b>3%</b>	<b>3%</b>	<b>3%</b>	<b>1%</b>	<b>44%</b>

# Soft tissue sarcoma – data completeness



Figure 4.6.9 TNM value completeness by registry




Figure 4.6.1 Tumour size completeness by registry







Figure 4.6.8 Grade completeness by registry





# Why do we need staging data?



Leiomysarcoma

Fibroblastic sarcoma





# *Thank you*

Thank you

- Matthew Francis
- Nicola Dennis

